Global Cardiac Marker Analyzer Market to 2025 - Product Analysis, Companies Business & Marketing Strategy, Major Deals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals” report has been added to ResearchAndMarkets.com’s offering.
The global Cardiac Marker Analyzer market is projected to exceed USD 4.3 Billion by 2025.
Cardiac Marker analyzer represents a paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others.
The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.
The factors such as increasing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.
Key Highlights of the ReportAbbott completed its acquisition of Alere, concluding a deal first announced in February 2016. Abbott Point of Care Diagnostics sales increased by 7.2 percent. Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin. Quidel’s cardiac immunoassay revenue was close to US$ 50 Million in 2017. A major focus of Response Biomedical development programs in cardiovascular testing has been clinical tests for the quantification of cardiovascular markers. Siemens Healthineers announced a digital platform for healthcare providers as well as for providers of solutions and services. CardioGenics is the only company to successfully deploy CL in a compact, fully automated POC platform. Trinity Biotech Point-of-Care revenues for 2017 is likely to decline. Abbott completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. Response Biomedical sells tests that detect three of the primary markers for the detection of an acute myocardial infarction: Troponin I, Myoglobin and CK-MB.
Key Topics Covered:
1. Executive Summary
2. Global Cardiac Marker Analyzer Market & Forecast (2011 - 2025)
3. Cardiac Marker Companies - Comparative Tests Analysis
4. Cardiac Marker Analyzer - Competitive Product Analysis
5. Alere (Now Abbott)
6. Quidel Corporation
7. Abbott Point of Care
9. Beckman Coulter
10. Siemens Healthineers
11. Response Biomedical
14. LSI Medience Corporation
15. CardioGenics Holdings Inc.
16. Trinity Biotech
17. Mergers, Acquisitions and Licensing Agreements
18. Emerging Markers
19. Response Biomedical - Business & Marketing Strategy
20. Roche - Business & Marketing Strategy
21. Boditech Med Inc - Business and Marketing Strategy
22. Siemens Healthineers - Business and Marketing Strategy
For more information about this report visit https://www.researchandmarkets.com/research/8tzj4d/global_cardiac?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005922/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/27/2018 04:26 PM/DISC: 09/27/2018 04:26 PM